A Causal Relationship Between Genetically Proxied Inhibition of HMGCR, NPC1L1, and PCSK9 and Cancers

References

[1] Y. Yang, G. Gao, J. Shi, et al., “Increased Blood Lipid Level Is Associated With Cancer-Specific Mortality and All-Cause Mortality in Patients With Colorectal Cancer (≥ 65 Years): A Population-Based Prospective Cohort Study,” Risk Management and Healthcare Policy 13 (2020): 855–863.

[2] T. B. Strøm, Ø. L. Holla, J. Cameron, K. E. Berge, and T. P. Leren, “Loss-of-Function Mutation R46L in the PCSK9 Gene Has Little Impact on the Levels of Total Serum Cholesterol in Familial Hypercholesterolemia Heterozygotes,” Clinica Chimica Acta 411 (2010): 229–233.

[3] X. Liu, X. Bao, M. Hu, et al., “Inhibition of PCSK9 Potentiates Immune Checkpoint Therapy for Cancer,” Nature 588 (2020): 693–698.

[4] N. Vallianou, A. Kostantinou, M. Kougias, and C. Kazazis, “Statins and Cancer,” Anti-Cancer Agents in Medicinal Chemistry 14 (2014): 706–712.

[5] Y. Yin, C. Wu, Y. Zhou, et al., “Ezetimibe Induces Paraptosis Through Niemann-Pick C1-Like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells,” Genes 15, no. 1 (2023): 4.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).